Hypoglycemia risk and its impact on daily life is always present for people with diabetes and their caregivers (CG) . With the goal of positively impacting the lives of those who use insulin, advances in glucagon and its delivery, have made it ready-to-use, expanding the community of people who could act in an emergency. This qualitative study elicited experiences from people who own one option, nasal glucagon (NG) . Semi-structured 1:1 interviews were conducted in the US with AwD and CGs of children or AwD following a pre-defined concept elicitation guide and analyzed thematically. The sample included 22 AwD (20 T1DM; 2 T2DM) and 7 CGs of people with T1DM (1 Adult, 6 Children) ; female (72%) ; mean age 38.7 years; college degree 59%; insulin pump 62%. Actual use of NG was reported by 46% of AwD and 43% of CGs. A total of 45 concepts were identified, the majority (81%) identified by the first 5 interviews; saturation (the point at which no new concepts emerge) reached at 25 interviews. The most frequently stated concepts were: feeling safe having NG on hand (93%) ; ease of use for others (90%) ; comfort in having NG as a rescue treatment option (90%) ; confidence in others’ ability to use NG (86%) ; ease of instruction to others (86%) (Figure) . These firsthand experiences give useful clinical insights regarding NG, deepening our understanding for practice considerations.
B.Mitchell: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. F.G.Sowell: None. P.Williams: None. J.Poon: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.
Eli Lilly and Company